139 related articles for article (PubMed ID: 18279063)
1. Taxanes in the management of gynecologic malignancies.
Markman M
Expert Rev Anticancer Ther; 2008 Feb; 8(2):219-26. PubMed ID: 18279063
[TBL] [Abstract][Full Text] [Related]
2. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.
Grothey A; Sargent DJ
J Clin Oncol; 2005 May; 23(15):3311-3. PubMed ID: 15908645
[No Abstract] [Full Text] [Related]
3. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
[TBL] [Abstract][Full Text] [Related]
4. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
Herceg D; Vrbanec D
Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer chemotherapy: emerging from the shadows.
Roth BJ
J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
[No Abstract] [Full Text] [Related]
7. Toxicity and compliance with a chemoradiotherapy schedule for advanced nasopharyngeal carcinoma: a single institution experience using the Intergroup 0099 study regimen.
Chajón EA; García-Berrocal MI; De la Fuente C; Regueiro C; Romero J; Valcárcel F; Magallón R; Hernanz R; De la Torre A
Acta Oncol; 2005; 44(1):85-6. PubMed ID: 15848912
[No Abstract] [Full Text] [Related]
8. Permanent interstitial reirradiation with 198Au as salvage therapy for low volume recurrent gynecologic malignancies: a single institution experience.
Brabham JG; Cardenes HR
Am J Clin Oncol; 2009 Aug; 32(4):417-22. PubMed ID: 19451799
[TBL] [Abstract][Full Text] [Related]
9. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.
Crown J; O'Leary M; Ooi WS
Oncologist; 2004; 9 Suppl 2():24-32. PubMed ID: 15161988
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic options for elderly patients with advanced non-small cell lung cancer.
Avery EJ; Kessinger A; Ganti AK
Cancer Treat Rev; 2009 Jun; 35(4):340-4. PubMed ID: 19155139
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
Schwartz J; Toste B; Dizon DS
Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E; Casillas M; Cassinello A
Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
[TBL] [Abstract][Full Text] [Related]
14. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
[TBL] [Abstract][Full Text] [Related]
15. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
Vaidya AP; Parnes AD; Seiden MV
Curr Treat Options Oncol; 2005 Mar; 6(2):103-14. PubMed ID: 15717992
[TBL] [Abstract][Full Text] [Related]
16. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia.
Lu H; Peng L; Yuan X; Hao Y; Lu Z; Chen J; Cheng J; Deng S; Gu J; Pang Q; Qin J
Cancer Treat Rev; 2009 Jun; 35(4):345-53. PubMed ID: 19211192
[TBL] [Abstract][Full Text] [Related]
19. [Cytostatic chemotherapy in advanced age].
Sauer H
Geburtshilfe Frauenheilkd; 1995 Jan; 55(1):M1-5. PubMed ID: 7705590
[No Abstract] [Full Text] [Related]
20. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
